Hanani 2026 — FM serum activates satellite glia across DRG, trigeminal, vagal, and sympathetic ganglia

One-paragraph summary

Following on from the Goebel 2021 passive-transfer paradigm, Hanani et al. asked whether the SGC-activating factor in FM serum is restricted to the dorsal root ganglion or operates across the wider peripheral ganglion system. They incubated mouse sensory ganglia of four distinct types — DRG (somatosensory), trigeminal (orofacial sensory), nodose (vagal afferent), and superior cervical (sympathetic) — with serum from 15 FM patients vs. 8 healthy controls. All four ganglion types showed SGC activation as measured by GFAP upregulation in immunostaining; healthy-control serum did not. The response was equivalent in male and female mice. This is mechanistically significant because it links the autoantibody hypothesis to the multi-system symptom profile of FM: orofacial pain (TG), autonomic dysregulation (SCG), vagal/gut-brain effects (NG), in addition to widespread musculoskeletal pain (DRG).

Claims as triples

• IgG_fm — modulates → satellite_glia [evidence: GFAP upregulation by immunostaining; confidence: emerging]
• IgG_fm — present_in → dorsal_root_ganglion [evidence: replicates Goebel 2021; confidence: emerging]
• IgG_fm — present_in → trigeminal_ganglion [evidence: GFAP upregulation; confidence: emerging — NEW]
• IgG_fm — present_in → nodose_ganglion [evidence: GFAP upregulation; confidence: emerging — NEW]
• IgG_fm — present_in → superior_cervical_ganglion [evidence: GFAP upregulation; confidence: emerging — NEW]
• autoantibody_mediated_pain — causes → autonomic_dysregulation [inferred from SCG activation; confidence: inferred]

Methods note

Serum from 15 FM patients and 8 healthy controls. Sera incubated with mouse DRG, trigeminal ganglion (TG), nodose ganglion (NG), and superior cervical sympathetic ganglion (Sup-CG). SGC activation read out by GFAP immunostaining. Sex-balanced (male and female mice tested separately, equivalent response). Author: Menachem Hanani (Hebrew University of Jerusalem) — well-established satellite-glia neurobiologist whose work predates and underpins much of the SGC-as-pain-mediator literature.

Limitations

• Preprint, not peer-reviewed. Status: preprint, awaiting peer review. Methodology and figures should be re-verified at publication.
• Small n (15 FM, 8 HC) — adequately powered for the binary "any signal" question but not for cluster analysis or subtype mapping.
• GFAP upregulation is a coarse readout for SGC activation; downstream functional consequences (neurotransmitter release, neuron sensitization) are inferred but not directly measured here.
• The authors don't fractionate IgG vs. other serum components — strictly speaking the "factor in FM serum" is not yet attributed to IgG in this study, only consistent with the Goebel 2021 attribution.
• Did not co-register with FM patient subtype (autoimmune-positive vs negative).

Open questions raised

• Does the SGC-activating factor's distribution across ganglia correlate with which FM symptoms a patient has? (E.g., do patients with prominent autonomic symptoms have stronger Sup-CG activation?)
• Does this same multi-ganglia activation occur in CRPS, ME/CFS, long-COVID patient sera? (Bridge-closing experiment.)
• Is the IgG fraction sufficient to reproduce the multi-ganglia activation, or does serum supply additional necessary factors?

Triangulation notes

• Major mechanistic advance: the multi-ganglia finding provides a unified mechanism for the multi-system symptom profile of FM. Previously this was the strongest argument against a single-cause autoimmune model (FM has too many symptoms to be one antibody). Now: the same antibody/factor activates SGCs in the ganglia upstream of each major symptom domain.
• Closes part of bridge B2 (gut-brain → glia) from a different angle: if FM IgG activates vagal SGCs (nodose ganglion), then the gut-brain axis is linked to the autoimmune mechanism without needing a separate microbiome → glial-state pathway. Worth noting alongside the Jakobsson 2026 bile-acid finding.
• Synergy with interoceptive_inference (newly added): vagal afferent dysfunction is a primary substrate for interoceptive disruption.

Bridges

• B2 (Microbiome → vagus → glia) — strengthened. NG SGC activation provides a direct vagal-side mechanism.
• B3 (CRPS ↔ FM via pathogenic IgG) — Hanani has parallel CRPS work; cross-reference candidate.
• B4 (ME/CFS ↔ FM via post-viral neuroimmune) — autonomic/Sup-CG involvement in FM via this mechanism is a candidate shared substrate with ME/CFS dysautonomia.